logo
episode-header-image
Jun 2021
11m 52s

FDA Approves Aducanumab — A Controversia...

NPR
About this episode
The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it.

For more of Jon's reporting, read "For Those Facing Alzheimer's, A Controversial Drug Offers Hope."

You can email Short Wave at ShortWave@NPR.org.

To manage podcast ad preferences, review the links below:

See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy
Up next
Today
A dietitian and doctor review RFK Jr's new food pyramid
The new food pyramid was released earlier this year. It emphasizes protein, full-fat dairy and what Health and Human Services Secretary Robert F. Kennedy Jr. calls “healthy fats.” These guidelines influence the standards for school lunches, food labeling and programs like SNAP. T ... Show More
12m 32s
Yesterday
‘Black rain’ in Iran and the environmental cost of war
US-Israeli airstrikes on oil depots culminated in ‘black rain’ in Iran early last week – a phenomenon usually caused by large amounts of soot, carbon and other pollutants in the air. Usually, rain leaves the atmosphere cleaner than it was before. But in this case, the rain left T ... Show More
12m 50s
Mar 16
This is your brain on pleasure (even the guilty kind)
It’s likely you have at least one “guilty pleasure.” Maybe it’s romance novels. Or reality TV… Playing video games… or getting swept into obscure corners of TikTok. Neuroscientists say the pleasure response helps us survive as a species. So why do we feel embarrassed by some of t ... Show More
13m 41s
Recommended Episodes
Aug 2021
Controversial new Alzheimer's drug in the spotlight
After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ... Show More
18m 21s
Jul 2021
'Some Hope Is Better Than Having No Hope'
<p>When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.</p><p>But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ... Show More
36m 59s
May 2024
This Is a Very Weird Moment in the History of Drug Laws
<p>Drug policy feels very unsettled right now. The war on drugs was a failure. But so far, the war on the war on drugs hasn’t entirely been a success, either.</p><p>Take Oregon. In 2020, it became the first state in the nation to decriminalize hard drugs. It was a paradigm shift ... Show More
1h 2m
Dec 2022
Declining ALS Patients Are Waiting On The FDA's Next Move
For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More
25m 57s